Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 2/20 | 0.35 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.35 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.35 |
| ▸ | KIT | P10721 | 4/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | UGCG | Q16739 | 7/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | GHSR | Q92847 | 4/20 | 0.32 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.32 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.32 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6481449 | 0.89 | F2 (0.39) | FLT3UGCGGHSR | |
| SCHEMBL6481377 | 0.87 | FOLH1 (0.30) | — | |
| SCHEMBL6493904 | 0.86 | S1PR1 (0.40) | SCN1ASCN2ASCN3AKITFLT3 | |
| SCHEMBL6483759 | 0.85 | SLC6A2 (0.33) | SCN1ASCN2ASCN3ACHRM3 | |
| SCHEMBL6490939 | 0.81 | ALDH1A1 (0.32) | GHSR | |
| SCHEMBL6489933 | 0.81 | GHSR (0.37) | GHSR | |
| SCHEMBL6481346 | 0.80 | MMP9 (0.43) | — | |
| SCHEMBL6491275 | 0.79 | GHSR (0.37) | SCN1ASCN2ASCN3AGHSR | |
| SCHEMBL6480782 | 0.77 | GHSR (0.46) | GHSR | |
| SCHEMBL6482638 | 0.76 | S1PR1 (0.39) | GHSRITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261332-A1 | Sulfonamides and uses thereof | ELIXIR PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261332-A1 | Sulfonamides and uses thereof | GLS2, STS, ABAT | SCN1A 494/4885SCN2A 634/4885SCN3A 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.